To address the question of how frequently this phenotype occurs in cells resistant to PI3K/mTOR inhibition, we investigated whether this mechanism also applied to three breast cancer cell lines resistant to Ku-0063794 and to four models of resistance to BYL719 (two of which were derived from esophagus and two from head and neck cancers). This evidence concerns the gene MTOR and breast carcinoma.